Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452479 | 0.93 | GAA (0.56) | GAAALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL23879242 | 0.93 | GAA (0.56) | GAAALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL23879277 | 0.87 | HTT (0.39) | GAAALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL23879249 | 0.85 | ALDH1A1 (0.46) | GAAALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL13892809 | 0.84 | ALDH1A1 (0.49) | GAAALDH1A1LMNAKMT2ACES2 | |
| SCHEMBL23879231 | 0.82 | LMNA (0.41) | GAAALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL4308385 | 0.82 | ALDH1A1 (0.53) | GAAALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL4318405 | 0.78 | ALDH1A1 (0.46) | GAAALDH1A1LMNAKMT2ACES2 | |
| SCHEMBL23879281 | 0.75 | ALDH1A1 (0.43) | GAAALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL30453150 | 0.75 | ALDH1A1 (0.43) | GAAALDH1A1HTTMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111253404-B | Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof | 上海医药集团股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3889156-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-111253404-A | Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof | 上海医药集团股份有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-8835682-B2 | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-7271181-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271181-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271181-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| US-20030096817-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096817-A1 | Inhibitors of p38 | MAPK1, MAPK3, MAP3K1 | GAA 2236/4885ALDH1A1 3189/4885HTT 3258/4885 |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | MAPK11, WEE1, NOS1 | GAA 4372/4885ALDH1A1 3002/4885HTT 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.